1 completed, 1 terminated, 1 withdrawn. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Terminated 1 |
Follow CP101: new trials by email Literature Review of CP101 trials Research Report on CP101
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) CP101, Placebo - Recurrent C. Difficile Infection | Phase 3 | Terminated | Finch Research and Development LLC. | 19 | 2021-11-15 | 2023-11-13 |
| Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) CP101, Placebo - Autism Spectrum Disorder, Autism | Phase 2 | Withdrawn | Finch Research and Development LLC. | 2020-05-01 | 2021-04-08 | |
| Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection CP101 - Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection | Phase 2 | Completed | Finch Research and Development LLC. | 132 | 2018-05-01 | 2022-08-30 |
Clostridium Infections (2) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Child Development Disorders, Pervasive (1) · Diabetes Insipidus, Neurogenic (1)
Finch Research and Development LLC. (3)
Canada (2) · United States (2)